2007
- Demerged from Sun Pharmaceutical Industries Limited
- SPARC listed on Bombay Stock Exchange and National Stock Exchange of India
2013
- US FDA approval received for LipodoxTM for treatment of ovarian cancer, multiple myeloma and AIDS related Kaposi’s sarcoma
2014
- US rights for XelprosR licensed to a subsidiary of Sun Pharma
2018
- US FDA approval received for Xelpros ® for the treatment of open-angle glaucoma or ocular hypertension
- USFDA approval received for ElepsiaTM as adjunctive therapy for the treatment of partial-onset seizures
2019
- Entered into licensing agreement with Bioprojet SCR to acquire exclusive rights for Vibozilimod
2020
- Entered into a worldwide license agreement for Vibozilimod with Sun Pharma
- Entered into a license agreement with Tripoint Therapeutics for ElepsiaTM
- New R&D facility set-up at Savli, Vadodara
2021
- Entered into license agreement with Visiox for PDP-716 (Brimonidine) and SDN-037 (Difluprednate)
- Entered into licensing agreement with Biomodifying for antibody (Anti MUC-1 antibody)
2022
- Entered into licensing agreement with SPI Inc. for SezabyTM (Phenobarbital sodium for Injection)
- Sezaby approved by USFDA under DESI guidelines
2023
- Entered into licensing agreement to acquire exclusive rights for SCD-153
- Formation of US subsidiary